Table 2 Safety summary in the safety-evaluable population

From: Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial

n (%)

ABCPem/Pac

(n = 152)

BCPem/Pac

(n = 153)

All-grade AE, any cause

151 (99.3)

153 (100)

Grades 3 and 4a

101 (66.4)

94 (61.4)

Grade 5

12 (7.9)

12 (7.8)

All-grade AE, treatment-relatedb

150 (98.7)

153 (100)

Grades 3 and 4a,c

102 (67.1)

95 (62.1)

Grade 5

9 (5.9)

10 (6.5)

Serious AE

64 (42.1)

52 (34.0)

Treatment-relatedb

56 (36.8)

49 (32.0)

AE leading to withdrawal from any treatment

35 (23.0)

23 (15.0)

Atezolizumab

11 (7.2)

8 (5.2)

Bevacizumab

22 (14.5)

16 (10.5)

Atezolizumab AESI

103 (67.8)

109 (71.2)

Grades 3 and 4a

17 (11.2)

11 (7.2)

Grade 5

2 (1.3)

1 (0.7)

Requiring use of systemic corticosteroid

28 (18.4)

15 (9.8)

Confirmed/suspected COVID-19

20 (13.2)

15 (9.8)

  1. aCounts in ‘grades 3 and 4’ are the number of patients whose highest grade of AEs are 3 or 4.
  2. bBased on investigator assessment of causality; related to any study drug.
  3. cPatients with unrelated grade 5 and related grades 3 and 4 AEs were included.
Back to article page